Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trial

Christopher Butler(West Virginia School of Osteopathic Medicine), Richard Hobbs(John Radcliffe Hospital), Monique Andersson, Philip Evans(University of Exeter), Dan V. Nicolau(Queensland University of Technology), Mona Bafadhel(National Institute for Health and Care Excellence), Oghenekome Gbinigie(University of Oxford), Sanjay Ramakrishnan(The University of Western Australia), Gail Hayward(University of Oxford), Peter J. Barnes(Imperial College London), Emma Ogburn(University of Oxford), Mark Fitzgerald(Berry & Associates (United States)), Ly‐Mee Yu(University of Oxford), Richard Russell(Southern Health NHS Foundation Trust), Oliver van Hecke(University of Oxford), Mahendra Patel(University of Oxford), Benjamin R. Saville(Vanderbilt University), Michelle A. Detry(Berry & Associates (United States)), Nicholas Berry(Berry & Associates (United States)), Christina Saunders(Berry & Associates (United States)), Nicholas Thomas(National Institute for Health and Care Excellence), Jienchi Dorward(Centre for the AIDS Programme of Research in South Africa), Simon de Lusignan(University of Oxford), Victoria Harris(University of Oxford)
medRxiv
April 12, 2021
Cited by 28


Related Papers